adesso (ADN1) H1 2024 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2024 earnings summary
1 Feb, 2026Executive summary
Sales increased 16% year-over-year to €631.1 million in H1 2024, driven almost entirely by organic growth and a 14–15% headcount expansion.
EBITDA rose 10% to €27.7 million, but consolidated earnings were negative at -€9.9 million, with EPS at -€1.51, due to higher depreciation, interest expenses, and lower capacity utilization.
All industries and regions showed growth, with Germany outperforming at 17% and the DACH region comprising 95% of total volume; international expansion continued with acquisitions in Turkey, Sweden, Italy, India, and Saudi Arabia.
The company maintained its sales target for 2024 but lowered its EBITDA guidance due to below-average capacity utilization, weak license sales, and higher costs.
Dividend per share increased to €0.70 for 2023, with a stated aim to raise dividends continuously.
Financial highlights
EBITDA margin was 4.4% in H1 2024, down from 4.6% in H1 2023, due to low capacity utilization and underperformance in the IT Solutions segment.
Net leverage improved by €28 million and net working capital by €40 million year-over-year; net debt position improved to -€115.4 million.
Free cash flow improved, reaching a record LTM per share of €9.41, supported by factoring.
Personnel costs per FTE up 2–17%; employee growth in line with sales growth.
Liquid assets increased to €52.1 million as of 30 June 2024.
Outlook and guidance
Full-year 2024 sales guidance maintained at above €1.25 billion, with H2 expected to be stronger due to improved utilization and more working days.
EBITDA guidance lowered to €80–110 million (from €110–130 million), still above last year’s €80 million.
IT services expected to remain strong, while IT solutions are forecasted to recover only in H2 2025.
Latest events from adesso
- Sales up 11% with margin pressure; H2 2025 expected to drive earnings recovery.ADN1
Q1 2025 TU3 Feb 2026 - Record sales and profitability in Q3 2024, with strong outlook and share buyback underway.ADN1
Q3 2024 TU14 Jan 2026 - Sales, EBITDA, and EPS surged, with robust sector growth and guidance at the upper end.ADN1
Q3 202515 Nov 2025 - 12% sales and 34% EBITDA growth in H1 2025, but free cash flow and equity ratio declined.ADN1
Q2 202518 Aug 2025 - 14% organic growth and margin gains set stage for further expansion in 2025.ADN1
H2 20245 Jun 2025